Proteolysis-targeting chimera (PROTAC) has been developed as a therapeutic modality and a powerful research tool for targeted protein degradation. A heterobifunctional PROTAC molecule consists of three elements: a ligand that binds to the target protein (TP), a ligand that binds to E3 ubiquitin ligase, and a linker that conjugates these two ligands. PROTAC is a fast and reversible chemical knockdown strategy that degrades the target protein through ubiquitin-proteosome system. Upon binding to the target protein, the PROTAC recruits E3 for the TP ubiquitination, which results in proteasome-mediated degradation.

https://www.profacgen.com/protac-discovery-and-development.html

Profacgen offers a full range of biopharmaceutical development and bio-manufacturing services that cover strategic consultancy, world-class process development, cGMP manufacturing, and analytical development.